The first melanoma patient treated with Neooncovac is feeling well and has developed the required immune response
The first patient to receive Russia’s personalized melanoma vaccine is feeling well and has developed the immune response needed to fight the disease, said Aleksandr Ginzburg, the scientific director of the Gamaleya Research Institute, which helped develop the treatment.
Last year, the Russian Health Ministry approved two domestically developed personalized cancer treatments: an mRNA-based vaccine for advanced melanoma named Neooncovac and a peptide medicine targeting colorectal cancer dubbed Oncopept.
Neooncovac was administered to its first patient in April. The recipient is a 60-year-old man with stage-three melanoma and metastases, who is being treated...
Read the full article here
